{"name":"OrphAI Therapeutics","slug":"orphai-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Apilimod Dimesylate Capsule","genericName":"Apilimod Dimesylate Capsule","slug":"apilimod-dimesylate-capsule","indication":"Relapsing multiple sclerosis","status":"phase_2"}]}],"pipeline":[{"name":"Apilimod Dimesylate Capsule","genericName":"Apilimod Dimesylate Capsule","slug":"apilimod-dimesylate-capsule","phase":"phase_2","mechanism":"Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator.","indications":["Relapsing multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOUnhyaVNsTUQwVy1HTjR4N2pVOEVOR3FoaHNOdHFBSHZlMmFoV0VSM3pLbjNhTU5kYzVJdlB6WkVodmJ5Zi1HUEQ1SjlsRC0xTHIzalJ5SmdGVmFXQzZ0dmY2SnNXSGlseVBFcFdtalNRTWlRdGVsM3JuSk1iNDJPRW11SlNyRTBUNUoxNnpyZGRsdUlPX1VPTUFDQ0t4NTRfd3c?oc=5","date":"2026-01-21","type":"trial","source":"The Clinical Trial Vanguard","summary":"Orphai’s LAM-001 Study Selected for ATS 2026 Presentation - The Clinical Trial Vanguard","headline":"Orphai’s LAM-001 Study Selected for ATS 2026 Presentation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV19SSmJGenRyTUxPR0twOHlwei1YNTVYUWNYVi1NaGoxU3NpYUdLQjNpamFnR3lKN3JXelRkeHdFWWdDeGRHUkg4YmNkcHFjLWhUNDJlVW5fX0xtQW1VUnVVdHA0d1l2X3RhTDNmUHJqUl9UUTJqZEpBVzdhLTI5SEVsS3lsODNxUG04OWdfUDE4T0hvMk9xUkVqaVNPd0dSOTMxb3U4YTZXTEttQ280SXRvek1uekJfVmZLYTFJWERNYkhoX0hyaWxHMm1Zcl9jcW1fekFyZ3I3MzNWbjlFVThCZG5aMHNDV1I3czZyZ19QZGR2cmlaNXJFSE9KVV9TejdEYXZaUEN3S1ZMNkNnR0JLSnFabXJMY3RIZmttTWx1MXVmZ0hLS0MwdE9aU2lxR2ZwajlqMG9mRzhFSEgwUw?oc=5","date":"2025-12-09","type":"pipeline","source":"PR Newswire","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQYmtyV3JOSE1tU19HWE1HQzgwRVhwYkJNUG1iLS1lQmtONW9BNGhFWDFUNmJVVW1ObU5ZYjhBZHExaDg5bjdtZjRvbERUbFdwVWU2NFZNWDdxbG1VVnVtZzFZUTMwa3d5UkMxZndxYWE5dHpNanJwUi1uTThCei1QNDhmX0JPWHhONV90bmhSazMtX1lDb0pzN2NRbTBpaUVoRTVBYXg3YkZ3SHVlZnRIZXVaRUtDZGNmUFlpTkpVY0hSSF80RjhKMVFUTVctelBNMGEtZVJTbk40Z251Vy13akJRRktuNU5qN3BrdjZmVlFHVnl4YnFNQ251cmc1Z01ha1M0REdKX29rYU02dFE?oc=5","date":"2025-07-24","type":"pipeline","source":"PR Newswire UK","summary":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight - PR Newswire UK","headline":"CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveIn","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-02-29","type":"pipeline","source":"GlobeNewswire","summary":"Bronchiolitis Obliterans Syndrome Market to Grow - GlobeNewswire","headline":"Bronchiolitis Obliterans Syndrome Market to Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPS1VYS1cwQ19tUGI1LVd2NFhFWmRveDZFX1c4c0pxTndLb2hEUWdwY1M1Y0hfQXN5VWx2aWRLYkNBWmRjTXF4NnVNUlY2a3hMNVVBTEFLUUpGVGlxdVNmSTJIMTZ6UTVDLVFuNm8tSHJVLUxyQzBTb212aC1reGg3OGpFY0FYUGt3QU93dFJjUklrVFlLSjVrZGtwNEx0bDg?oc=5","date":"2024-01-24","type":"pipeline","source":"citybiz","summary":"OrphAI Therapeutics Appoints Jay Fine to Board of Directors - citybiz","headline":"OrphAI Therapeutics Appoints Jay Fine to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNeFViZ3MwX2NuZHZqUUtkNGlxc25HQ0VMUmMzcmhNWWxUTWdmdzV6Tm5TVzZXZWY2ZG0xM2xkQ011RnBFYzdsOGRCbUVidTUyOXBvRGRrOGhfZnMtYmtSTEVpMTlZekhLQ2VHSXc2TWhORXRucy1CcGs3S2J5LWc5STNsd2w4T0FxRVo5Vnp6eWlENkJvVEI5ejAxTXczdVBLWGNmQWRNZU8zYWVhLW5PenZxS2pUMFZ3OHNSQXdXMXJxNWNyWWQ4VGI3VExJVzl4U2xsdENaWk9XY1k1?oc=5","date":"2022-02-16","type":"pipeline","source":"GlobeNewswire","summary":"AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer - GlobeNewswire","headline":"AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}